ArticleBMC nephrology2015
NephroCheck data compared to serum creatinine in various clinical settings.
Article in BMC nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Biomarker-guided acute kidney injury risk assessment under liberal versus restrictive fluid therapy - the prospective-randomized MAYDAY-trial.Scientific reports · 2024Trial
- Urinary biomarkers IGFBP7 and TIMP-2 in the ICU: a multicenter prospective study on acute kidney injury outcomes.Annals of intensive care · 2026Article
- Urinary Biomarkers for Cell Cycle Arrest TIMP-2 and IGFBP7 for Prediction of Graft Function Recovery after Kidney Transplantation.International journal of molecular sciences · 2024Observational
- Cell cycle arrest biomarkers for the early detection of acute allograft dysfunction and acute rejection in living donor kidney transplantation: a cross-sectional study from Egypt.Korean journal of transplantation · 2023Article
- NephroCheck at 10: addressing unmet needs in AKI diagnosis and risk stratification.Clinical kidney journal · 2023Article
- Urinary Collectrin (TMEM27) as Novel Marker for Acute Kidney Injury.Life (Basel, Switzerland) · 2022Article
- Role of Urinary Kidney Stress Biomarkers for Early Recognition of Subclinical Acute Kidney Injury in Critically Ill COVID-19 Patients.Biomolecules · 2022Article
- Serum Creatinine Levels and Nephrocheck® Values With and Without Correction for Urine Dilution-A Multicenter Observational Study.Frontiers in medicine · 2022Article
- Article
- Dynamic 2-deoxy-2[18F] fluoro-D-glucose PET/MRI in human renal allotransplant patients undergoing acute kidney injury.Scientific reports · 2020Observational
- Article
- Spinal Reflex Recovery after Dorsal Rhizotomy and Repair with Platelet-Rich Plasma (PRP) Gel Combined with Bioengineered Human Embryonic Stem Cells (hESCs).Stem cells international · 2020Article
- Role of biomarkers as predictors of acute kidney injury and mortality in decompensated cirrhosis.Scientific reports · 2019Article
- Article
- Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel.Critical care (London, England) · 2019Article
- Lack of impact of iodinated contrast media on kidney cell-cycle arrest biomarkers in critically ill patients.BMC nephrology · 2018Observational
- Mechanisms Underlying Increased TIMP2 and IGFBP7 Urinary Excretion in Experimental AKI.Journal of the American Society of Nephrology : JASN · 2018Article
- Renal Dysfunction: How to Think About That in Acute Coronary Syndromes.Current cardiology reports · 2017Review
- Urinary neprilysin in the critically ill patient.BMC nephrology · 2017Article
- Heme Oxygenase 1 as a Therapeutic Target in Acute Kidney Injury.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury is frequently observed at the intensive care unit, after surgery, and after toxic drug administration. A rise in serum creatinine and a fall in urine output are consequences of much earlier injury to the most sensitive part of tubular cells located at the proximal tubule. The aim of the present study was to investigate the course of two cell-cycle arrest urinary biomarkers compared to serum creatinine in four clinical settings: ischemic reperfusion injury, cardiac failure, severe acute kidney injury, and chemotherapy-induced kidney injury.
methodsA recently developed bedside test known as NephroCheck measures two urinary parameters: insulin-like growth factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinase-2 (TIMP-2). The test is based on a sandwich immunoassay technique. The final test output, labeled AKIRisk, is shown as a numeric result.
resultsThis report revealed that [IGFBP7] · [TIMP-2] in urine rise rapidly prior to any change in serum creatinine. A unique feature of all four clinical settings is that a rapid decline predicts the recovery of kidney function. Besides, a subclinical kidney injury might be detected by the test.
conclusionThis bedside test detects biomarkers of renal injury. A rapid decline in AKIRisk was associated with the restoration of kidney function, whereas a prolonged high AKIRisk score was associated with end-stage renal disease. However, the dynamics seem to differ, depending on the cause and the extent of injury. Further studies will be needed to clarify the issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.